Tasisulam is a anticancer agent and induces apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell death. Tasisulam inhibits mitotic progression and induces vascular normalization.

Tasisulam sodium (200 nM-200 μM; 48 hours) induces an antiproliferative response across a wide range of tumor histologies with EC 50 s of 10 μM and 25 μM for Calu-6 and A-375 cell lines, respectively[1]. Tasisulam sodium (25, 50 μM; 72 hours) induces a concentration-dependent increase in 4N DNA and G2-M accumulation[1]. Tasisulam sodium (200 nM-200 μM; 48 hours) induces apoptosis in a broad range of in vitro cancer cell models[1]. Tasisulam sodium also blocks VEGF, epidermal growth factor, and fibroblast growth factor-induced endothelial cell cord formation[1]. Cell Proliferation Assay[1]Cell Line: Calu-6 non-small cell lung carcinoma and A-375 melanoma models Concentration: 200 nM-200 μM Incubation Time: 48 hours Result: Induced an antiproliferative response across a wide range of tumor histologies with EC 50 s is 10 μM and 25 μM, respectively. Cell Cycle Analysis[1]Cell Line: Calu-6 and A-375 cell lines Concentration: 25, 50 μM Incubation Time: 72 hours Result: Induced a concentration-dependent increase in 4N DNA and G2-M accumulation. Apoptosis Analysis[1]Cell Line: Calu-6 non-small cell lung carcinoma and A-375 melanoma models Concentration: 200 nM-200 μM Incubation Time: 48 hours Result: Induced apoptosis in a broad range of in vitro cancer cell models.

519055-63-1

C11H6BrCl2NNaO3S2

438.1

Tasisulam sodium;LY 573636 sodium;Tasisulam sodium

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years